The company is pleased with data it has collected to date for NanaBis.
’s () CEO Dr Sean Hall last night, presented a clinical NanaBis update to medical practitioners as part of on-going medical education.
He explained several key aspects of NanaBis, which is a highly purified proprietary blend of cannabis molecules cannabidiol (CBD) and tetrahydrocannabinol (THC).
A summary was provided of five case studies from five different doctors that were treated with NanaBis™ in Australia under the government-approved Special Access Scheme (SAS).
Notably, the data shows significant improvements in quality of life inclusive of sleep and movement with reduced pain/restriction, reduction/replacement of previously prescribed medication (in particular opioids, reduction in pain severity scores, and reduction of symptoms.
READ: Medlab Clinical does deal for global distribution of NanaBis
Medlab noted that it is extremely pleased with the pooled data collected to date as well as the ongoing regulatory pathway for an approved drug.
NanaBis wins head-to-head with approved cannabis drug
Further to previously announced Stage 1 results, NanaBis™ data from that component of the trial was directly compared to published data for an ARTG approved Cannabis Drug.
The head to head comparison demonstrates a similar plasma level of THC and CBD with NanaBis being half the dose.
Similarly, the rate of absorption for NanaBis was faster.
Actively pursuing drug approval
Based on trial activity, Medlab is actively pursuing regulatory pathways for TGA in Australia, FDA in the US and Europe’s EMA.
Medlab has a planned framework that should take NanaBis to an approved drug.
Proactive caught up with Dr Hall earlier this week for an update
